Dihydrocodeine
Dihydrocodeine is a semi-synthetic opioid analgesic of the morphinan class. Developed in Germany in 1908 and first marketed in 1911, it was originally created during efforts to find more effective antitussive medications to curb the spread of airborne diseases like tuberculosis. Slightly more potent than codeine, it is prescribed for moderate to severe pain, dyspnea, and cough suppression. It is commonly sold in combination formulations containing paracetamol or aspirin, which pose additional overdose risks if not accounted for.
Contents
Dosage & Duration
Dosage
When using combination products that contain dihydrocodeine alongside paracetamol (acetaminophen) or other active ingredients, cold water extraction may be employed to separate the opioid component and reduce exposure to potentially hepatotoxic doses of the additional substances.
Duration
Subjective Effects
Effects vary widely by individual, dose, and context.
Physical
The physical effects of dihydrocodeine can be broken down into several components which progressively intensify proportional to dosage.
Cognitive
The cognitive effects of dihydrocodeine can be broken down into several components which progressively intensify proportional to dosage. The general head space of dihydrocodeine is described by many as one of intense euphoria, relaxation, anxiety suppression and pain relief.
Reagent Testing
Loading reagent data
Pharmacology
Pharmacodynamics
Dihydrocodeine exerts its analgesic effects primarily through agonist activity at μ-opioid receptors, with lesser contributions from κ-opioid and δ-opioid receptors. Its affinity at the δ-opioid receptor is approximately 5 to 50 times weaker than at the μ-opioid receptor, while its κ-opioid affinity is comparable to that of codeine and morphine. The parent compound is itself pharmacologically active and is considered the primary contributor to analgesia.
Pharmacokinetics
Dihydrocodeine has low oral bioavailability (approximately 20%), attributable to poor gastrointestinal absorption and extensive first-pass metabolism by the liver and intestinal wall. It is metabolized hepatically via CYP2D6 (O-demethylation to dihydromorphine) and CYP3A4 (N-demethylation to nordihydrocodeine), with additional glucuronide conjugation producing dihydrocodeine-6-glucuronide (DHC-6-G), which itself contributes to the overall analgesic effect. Due to this multidirectional metabolic pathway, CYP2D6 metabolizer status does not appear to significantly influence analgesia, as pain threshold and pupillary responses do not differ between poor and extensive metabolizers. The mean elimination half-life is approximately 4 hours, with linear pharmacokinetics and plasma clearance of roughly 300 mL/min.
Dangerous
Highest riskThese combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
Unsafe
AvoidThere is considerable risk of physical harm when taking these combinations, they should be avoided where possible.
Caution
Use cautionThese combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
Tolerance
Opioids (dihydrocodeine has demonstrated cross-tolerance with other opioids and has historically been used to manage morphine withdrawal)
Harm Potential
Addiction & Dependence
Psychological
ModerateDihydrocodeine produces euphoria at higher-than-therapeutic doses and is commonly used recreationally. Psychological dependence develops with repeated use, as is characteristic of opioids.
Physical
HighPhysical dependence develops with repeated use. Dihydrocodeine has demonstrated cross-tolerance with other opioids and has historically been used to manage morphine withdrawal.
History & Culture
Discovery and Development
Dihydrocodeine is a semi-synthetic opioid that was developed in Germany in 1908 during a period of intensive research into more effective antitussive agents. This effort was motivated by the urgent need to limit the transmission of airborne infectious diseases, particularly tuberculosis, pertussis,…
Legality
By Country
References
Source Pages
Further Reading
Ammon et al. 1999 - Pharmacokinetics of DHC and DHM (DOI)- Kirkwood et al. 1997 - Cytochrome P450 metabolism (DOI)
- Leppert 2010 - DHC as opioid analgesic (DOI)
- Rowell et al. 1983 - Pharmacokinetics IV and oral (DOI)
- Schmidt et al. 2002 - Opioid receptor affinities (DOI)
- Schmidt et al. 2003 - Role of active metabolites (DOI)
Automated synthesisInformation aggregated and synthesized using an autonomous workflow built by Josie Kins.
Suggest an edit
Spotted a mistake, an outdated claim, or something missing from the Dihydrocodeine article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.